Novavax
NASDAQ · NVAX·Gaithersburg, MD·Small-cap·Approved
Vaccine company built around recombinant protein nanoparticle technology and the proprietary Matrix-M saponin adjuvant. Pivoting from in-house COVID-19 commercialization to a partnership-driven model with Sanofi (commercial COVID/combination programs) and Pfizer (Matrix-M for additional pipeline indications), while advancing standalone flu and CIC combination vaccine candidates.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Novavax Corporate Presentation — March 2026 | Corporate overview | March 15, 2026 | 27 |